As compared with a high level of BECN1 mRNA expression, a low level of BECN1 mRNA expression was strongly associated with HER2-enriched breast tumors (odds ratio 5.5 [95% CI 4.0 to 7.7], P = 1.4E− 30); with basal-like breast tumors (odds ratio 10.0 [95% CI 7.3 to 14.1], P = 1.4E− 61); with TP53 mutations (odds ratio 3.0 [95% CI 1.9 to 4.8], P = 8.9E− 07); and with tumor grade III (odds ratio 2.9 [95% CI 2.0 to 4.1], P = 5.8E− 10). This evidence concerns the gene ERBB2 and neoplasm.